3D Primary Cell Culture: A New Promising Preclinical Model for Pancreatic Neuro-Endocrine Tumors (pNETs). Abstract #1638

Introduction: The lack of adequate in vitro and in vivo preclinical models has hampered the identification of novel treatment options and the development of personalized therapy selection for pNET patients.
Aim(s): to establish 3D culture of primary pNETs, which are viable, metabolic active and phenotypically comparable to the tumor of origin for several days after isolation.
Materials and methods: Cells are isolated from pNET specimens and cultivated for 12-15 days. Treatments start at day 3 and last until day 9-10. Growth and cell viability are monitored until the end of the experiment. Spheroids are fixed and embedded in paraffin for IHC staining on proliferation, cell death and specific neuroendocrine phenotypic markers, for comparison to the original tumor tissue.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Ilaria Marinoni

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1111 Autophagy as a Possible Mechanism of Resistance in pNET Treatment
Introduction: Pancreatic neuroendocrine tumor (pNET) patients often display primary or secondary resistance to Sunitinib, an anti-angiogenic multi-receptor tyrosine kinase inhibitor which has been approved for the treatment of late stage pNETs. In late cancer stage autophagy often has a tumor promoting role. Sunitinib might additionally activate autophagy through inhibition of mTOR or induction of hypoxia.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Tabea Wiedmer
#1850 Influence of VEGF Splicing on Microvessel Density and Architecture in Pancreatic Neuroendocrine Tumours
Introduction: Hypoxia in human tumours is associated with a poor prognosis and is characterized by the stabilization of HIF1α, upregulation of VEGF, and a high microvessel density (MVD). Interestingly, although pancreatic neuroendocrine tumours (pNETS) showing hypoxia signalling also have a poor prognosis, they paradoxically display a low MVD. We hypothesized that this paradoxon might be explained by alternative splicing of VEGF.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: MD Anja Maria Schmitt
Authors: Marinoni I, Naim S, Centeno I, Perren A, ...
Keywords: pNET, VEGF
#613 Preclinical Evaluation of Novel Combinations of 177-Lutetium Octreotate with Molecular Targeted Agents in Neuroendocrine Tumor Models
Introduction: Peptide receptor radionuclide therapy (PRRT) has been valuable in the treatment of somatostatin receptor-2 (SSTR2) expressing neuroendocrine tumors (NET) but more effective clinical regimens are needed.
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Carleen Cullinane
Authors: Cullinane C, Waldeck K, Kirby L, Eu P, ...
#1312 Epigenetic Remodeling upon DAXX and ATRX Loss in Pancreatic Neuro-endocrine tumors (pNETs)
Introduction: DAXX and or ATRX loss occur in 40% of sporadic pNETs. DAXX and ATRX participate in the cell epigenetic status maintenance. Epigenetic changes influence gene expression, function of telomeres and genomic stability. We hypothesize that DAXX/ATRX loss drives tumor progression in pNET through epigenetic changes affecting genomic stability.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Ilaria Marinoni
Keywords: DAXX/ATRX, epigenetic, CIN
#2271 Effects of Multi-Receptor Targeting Drugs in Neuroendocrine Tumors Using 3D Cell Culture
Introduction: Symptom control in functioning neuroendocrine tumors(NETs) may be difficult in some cases, thus, new therapeutic options, including multi-receptor targeting drugs are required.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Aura Dulcinea Herrera-Martínez